Propanc Biopharma, Inc. (OTC: PPCB) 宣布,其领先研发资产PRP在针对胰腺癌的临床前研究模型中,展现出超过85%的肿瘤生长抑制效果。这一积极数据进一步验证了PRP作为潜在抗癌疗法的有效性,特别是在治疗胰腺癌这一难治性癌症领域显示出巨大潜力。
Propanc Biopharma, Inc. (OTC: PPCB) 宣布,其领先研发资产PRP在针对胰腺癌的临床前研究模型中,展现出超过85%的肿瘤生长抑制效果。这一积极数据进一步验证了PRP作为潜在抗癌疗法的有效性,特别是在治疗胰腺癌这一难治性癌症领域显示出巨大潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.